Modulation of body temperature and LH secretion by h

Frontiers in Neuroendocrinology

34, 211-227

DOI: 10.1016/j.yfrne.2013.07.003

Citation Report

#	Article	IF	Citations
1	Disparate Changes in Kisspeptin and Neurokinin B Expression in the Arcuate Nucleus After Sex Steroid Manipulation Reveal Differential Regulation of the Two KNDy Peptides in Rats. Endocrinology, 2014, 155, 3945-3955.	1.4	31
2	Electrophysiology of Arcuate Neurokinin B Neurons in Female Tac2-EGFP Transgenic Mice. Endocrinology, 2014, 155, 2555-2565.	1.4	19
3	The kisspeptin-GnRH pathway in human reproductive health and disease. Human Reproduction Update, 2014, 20, 485-500.	5.2	373
4	Hypothalamic Molecular Changes Underlying Natural Reproductive Senescence in the Female Rat. Endocrinology, 2014, 155, 3597-3609.	1.4	24
5	Estradiol Regulates Brown Adipose Tissue Thermogenesis via Hypothalamic AMPK. Cell Metabolism, 2014, 20, 41-53.	7.2	342
6	Adiposity-Related Cancer and Functional Imaging of Brown Adipose Tissue. Endocrine Practice, 2015, 21, 1282-1290.	1.1	7
7	Î² Agonists as a novel therapy for menopausal hot flashes. Menopause, 2015, 22, 1328-1334.	0.8	24
8	Neurokinin 3 Receptor-Expressing Neurons in the Median Preoptic Nucleus Modulate Heat-Dissipation Effectors in the Female Rat. Endocrinology, 2015, 156, 2552-2562.	1.4	33
9	Animal Models in Menopause Research. Women's Reproductive Health, 2015, 2, 29-32.	0.3	1
10	Chronic Oestradiol Reduces the Dendritic Spine Density of <scp>KND</scp>y (Kisspeptin/Neurokinin) Tj ETQq1 1 0.784314 rgBT /Overl Protein Transgenic Mice. Journal of Neuroendocrinology, 2015, 27, 253-263.	1.2	19
11	Neuropeptide co-expression in hypothalamic kisspeptin neurons of laboratory animals and the human. Frontiers in Neuroscience, 2015, 9, 29.	1.4	66
12	Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis. Breast Cancer Research and Treatment, 2015, 152, 231-237.	1.1	35
13	Estrogens and the control of energy homeostasis: a brain perspective. Trends in Endocrinology and Metabolism, 2015, 26, 411-421.	3.1	103
14	Effects of Phoenixin-14 on anxiolytic-like behavior in mice. Behavioural Brain Research, 2015, 286, 39-48.	1.2	70
15	Minireview: Neural Signaling of Estradiol in the Hypothalamus. Molecular Endocrinology, 2015, 29, 645-657.	3.7	38
16	Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3975-4011.	1.8	589
17	The Role of Kisspeptin in the Onset of Puberty and in the Ovulatory Mechanism: A Mini-review. Journal of Pediatric and Adolescent Gynecology, 2015, 28, 286-291.	0.3	42
18	Neurokinin B. , 2016, , 76-77.		0

#	Article	IF	Citations
19	Effects of Chronic Estrogen Administration in the Ventromedial Nucleus of the Hypothalamus (VMH) on Fat and Bone Metabolism in Ovariectomized Rats. Endocrinology, 2016, 157, 4930-4942.	1.4	11
20	Treatment with an orally bioavailable prodrug of 17Î²-estradiol alleviates hot flushes without hormonal effects in the periphery. Scientific Reports, 2016, 6, 30721.	1.6	19
21	Hot flushes and reproductive hormone levels during the menopausal transition. Maturitas, 2016, 89, 43-51.	1.0	21
22	Effects of Testosterone and Estradiol Deficiency on Vasomotor Symptoms in Hypogonadal Men. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3479-3486.	1.8	13
23	Sex hormone effects on autonomic mechanisms of thermoregulation in humans. Autonomic Neuroscience: Basic and Clinical, 2016, 196, 75-80.	1.4	101
24	Kisspeptin as a therapeutic target in reproduction. Expert Opinion on Therapeutic Targets, 2016, 20, 567-575.	1.5	10
25	Hot flashes and midlife symptoms in relation to levels of salivary cortisol. Maturitas, 2017, 96, 26-32.	1.0	11
26	Sex differences in variability across timescales in BALB/c mice. Biology of Sex Differences, 2017, 8, 7.	1.8	56
27	Investigational and experimental GnRH analogs and associated neurotransmitters. Expert Opinion on Investigational Drugs, 2017, 26, 661-667.	1.9	10
28	A Comprehensive Method To Quantify Adaptations by Male and Female Mice With Hot Flashes Induced by the Neurokinin B Receptor Agonist Senktide. Endocrinology, 2017, 158, 3259-3268.	1.4	15
29	Premature Ovarian Insufficiency: An Adolescent Series. Journal of Pediatric and Adolescent Gynecology, 2017, 30, 615-619.	0.3	7
30	Maternal and Early-Life Circadian Disruption Have Long-Lasting Negative Consequences on Offspring Development and Adult Behavior in Mice. Scientific Reports, 2017, 7, 3326.	1.6	49
31	Association of genetic variation in the tachykinin receptor 3 locus with hot flashes and night sweats in the Women's Health Initiative Study. Menopause, 2017, 24, 252-261.	0.8	56
32	Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet, The, 2017, 389, 1809-1820.	6.3	149
33	New pathways in the treatment for menopausal hot flushes. Lancet, The, 2017, 389, 1775-1777.	6.3	8
34	Estradiol effects on hypothalamic AMPK and BAT thermogenesis: A gateway for obesity treatment?. , 2017, 178, 109-122.		53
35	The menopausal hot flush: a review. Climacteric, 2017, 20, 296-305.	1.1	52
36	Neurokinin 3 receptor antagonism â€“ the magic bullet for hot flushes?. Climacteric, 2017, 20, 505-509.	1.1	8

#	Article	IF	Citations
37	Nitric oxide-heat shock protein axis in menopausal hot flushes: neglected metabolic issues of chronic inflammatory diseases associated with deranged heat shock response. Human Reproduction Update, 2017, 23, 600-628.	5.2	27
38	Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3647-3661.	1.8	89
39	Estradiol for the mitigation of adverse effects of androgen deprivation therapy. Endocrine-Related Cancer, 2017, 24, R297-R313.	1.6	13
40	Neuroendocrine Aging: Hypothalamicâ€“Pituitaryâ€“Gonadal Axis in Womenâ˜†. , 2017, , .		0
41	Schisandrae Fructus Reduces Symptoms of 4-Vinylcyclohexene Diepoxide-Induced Ovarian Failure in Mice. Evidence-based Complementary and Alternative Medicine, 2017, 2017, 1-9.	0.5	3
42	Sleep and Menopause. , 2017, , 1553-1563.e5.		1
43	The 3rd World Conference on Kisspeptin, â€œKisspeptin 2017: Brain and Beyondâ€• Unresolved questions, challenges and future directions for the field. Journal of Neuroendocrinology, 2018, 30, e12600.	1.2	12
44	Vasomotor symptoms: natural history, physiology, and links with cardiovascular health. Climacteric, 2018, 21, 96-100.	1.1	49
45	Three-dimensional imaging of KNDy neurons in the mammalian brain using optical tissue clearing and multiple-label immunocytochemistry. Scientific Reports, 2018, 8, 2242.	1.6	15
46	What's in a name: are menopausal â€œhot flashesâ€•a symptom of menopause or a manifestation of neurovascular dysregulation?. Menopause, 2018, 25, 700-703.	0.8	21
47	Symptoms of menopause â€" global prevalence, physiology and implications. Nature Reviews Endocrinology, 2018, 14, 199-215.	4.3	344
48	Kisspeptin modulates pain sensitivity of CFLP mice. Peptides, 2018, 105, 21-27.	1.2	8
49	Diverse actions of estradiol on anorexigenic and orexigenic hypothalamic arcuate neurons. Hormones and Behavior, 2018, 104, 146-155.	1.0	40
50	Neurokinin 3 Receptor Antagonism Reveals Roles for Neurokinin B in the Regulation of Gonadotropin Secretion and Hot Flashes in Postmenopausal Women. Neuroendocrinology, 2018, 106, 148-157.	1.2	55
51	Molecular identification of the Dyn/Kor system and its potential role in the reproductive axis of goldfish. General and Comparative Endocrinology, 2018, 257, 29-37.	0.8	11
52	Estradiol alters body temperature regulation in the female mouse. Temperature, 2018, 5, 56-69.	1.6	22
54	Association of vasomotor symptoms and sleep apnea risk in midlife women. Menopause, 2018, 25, 391-398.	0.8	16
55	The thermoregulation system and how it works. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 156, 3-43.	1.0	91

#	Article	IF	Citations
56	Onset of the Menopause Transition. Obstetrics and Gynecology Clinics of North America, 2018, 45, 585-597.	0.7	92
57	Extranuclear signaling by ovarian steroids in the regulation of sexual receptivity. Hormones and Behavior, 2018, 104, 4-14.	1.0	13
58	Neural Secretions and Regulation of Gut Functions. , 2018, , 527-684.		1
59	The role of kisspeptin/neurokinin B/dynorphin neurons in pathomechanism of vasomotor symptoms in postmenopausal women: from physiology to potential therapeutic applications. Gynecological Endocrinology, 2018, 34, 913-919.	0.7	16
60	Sex-Specific Physiology and Cardiovascular Disease. Advances in Experimental Medicine and Biology, 2018, 1065, 433-454.	0.8	96
61	The Management of Menopausal Symptoms in Women Following Breast Cancer: An Overview. Drugs and Aging, 2018, 35, 699-705.	1.3	2
62	A Neural Circuit Underlying the Generation of Hot Flushes. Cell Reports, 2018, 24, 271-277.	2.9	91
63	Sleep problems during the menopausal transition: prevalence, impact, and management challenges. Nature and Science of Sleep, 2018, Volume 10, 73-95.	1.4	166
64	Evidence for a Coupled Oscillator Model of Endocrine Ultradian Rhythms. Journal of Biological Rhythms, 2018, 33, 475-496.	1.4	28
65	KNDy Cells Revisited. Endocrinology, 2018, 159, 3219-3234.	1.4	144
66	Vasomotor and Related Menopause Symptoms. Clinical Obstetrics and Gynecology, 2018, 61, 433-446.	0.6	6
67	TRPCing around the hypothalamus. Frontiers in Neuroendocrinology, 2018, 51, 116-124.	2.5	16
68	Neurokinin 3 receptor antagonists for treatment of vasomotor symptoms: a new panacea or just a flash in the pan?. Menopause, 2018, 25, 859-861.	0.8	6
69	Neuroendocrine Control of the Menstrual Cycle. , 2019, , 149-166.e5.		19
70	Diagnosis of Menopause. , 2019, , 628-633.		0
71	Symptoms and Hormones: Fine-Tuning Atherosclerotic Risk?. ISGE Series, 2019, , 265-269.	0.2	0
72	Determining the relationship between hot flushes and LH pulses in menopausal women using mathematical modelling. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3628-3636.	1.8	6
73	Effects of severe whole-body hyperthermia on ovarian hormone and extracellular Hsp72 responses in young adult women. International Journal of Hyperthermia, 2019, 36, 659-664.	1.1	3

#	Article	IF	Citations
74	Kisspeptin/Neurokinin B/Dynorphin (KNDy) cells as integrators of diverse internal and external cues: evidence from viral-based monosynaptic tract-tracing in mice. Scientific Reports, 2019, 9, 14768.	1.6	52
75	Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5893-5905.	1.8	62
76	Cognition, Mood and Sleep in Menopausal Transition: The Role of Menopause Hormone Therapy. Medicina (Lithuania), 2019, 55, 668.	0.8	66
77	Oral investigational drugs currently in phase I or phase II for the amelioration of menopausal symptoms. Expert Opinion on Investigational Drugs, 2019, 28, 235-247.	1.9	8
78	The neurokinin B pathway in the treatment of menopausal hot flushes. Climacteric, 2019, 22, 51-54.	1.1	10
79	Managing vasomotor symptoms in women after cancer. Climacteric, 2019, 22, 544-552.	1.1	18
80	Prolactin â€" a pleiotropic factor in health and disease. Nature Reviews Endocrinology, 2019, 15, 356-365.	4.3	148
81	Episodic Ultradian Eventsâ€"Ultradian Rhythms. Biology, 2019, 8, 15.	1.3	52
82	Glutamatergic Neurokinin 3 Receptor Neurons in the Median Preoptic Nucleus Modulate Heat-Defense Pathways in Female Mice. Endocrinology, 2019, 160, 803-816.	1.4	29
83	Longitudinal course of vasomotor symptoms in perimenopausal migraineurs. Annals of Neurology, 2019, 85, 865-874.	2.8	13
84	Novel Biology of Tachykinins in Gonadotropin-Releasing Hormone Secretion. Seminars in Reproductive Medicine, 2019, 37, 109-118.	0.5	10
85	Menopausal night sweats: more evidence for long-term repercussions of childhood abuse on women's health. Menopause, 2019, 26, 1085-1087.	0.8	0
86	Neurokinin B and Neurokinin-3 Receptor Signaling: Promising Developments in the Management of Menopausal Hot Flushes. Seminars in Reproductive Medicine, 2019, 37, 125-130.	0.5	8
87	Adverse Effects of Aromatase Inhibition on the Brain and Behavior in a Nonhuman Primate. Journal of Neuroscience, 2019, 39, 918-928.	1.7	37
88	New Perspectives for Anatomical and Molecular Studies of Kisspeptin Neurons in the Aging Human Brain. Neuroendocrinology, 2019, 109, 230-241.	1.2	21
89	Neurokinin 3 Receptor Antagonism: A Novel Treatment for Menopausal Hot Flushes. Neuroendocrinology, 2019, 109, 242-248.	1.2	37
90	Gonadotropin-Releasing Hormone (GnRH) Development and Actions. , 2019, , 692-694.		1
91	Effect of sulpiride on menopausal hot flashes: a randomized, double-blind, placebo-controlled clinical trial. Gynecological Endocrinology, 2020, 36, 247-251.	0.7	1

#	Article	IF	Citations
92	Variation in menopausal vasomotor symptoms outcomes in clinical trials: a systematic review. BJOG: an International Journal of Obstetrics and Gynaecology, 2020, 127, 320-333.	1.1	19
93	Kisspeptin and neurokinin B analogs use in gynecological endocrinology: where do we stand?. Journal of Endocrinological Investigation, 2020, 43, 555-561.	1.8	15
94	Neurokinin 3 Receptor Antagonists Do Not Increase FSH or Estradiol Secretion in Menopausal Women. Journal of the Endocrine Society, 2020, 4, bvz009.	0.1	5
95	A selective serotonin receptor agonist for weight loss and management of menopausal vasomotor symptoms in overweight midlife women: a pilot study. Menopause, 2020, 27, 1228-1235.	0.8	6
96	Pharmacodynamic Activity of the Novel Neurokinin-3 Receptor Antagonist SJX-653 in Healthy Men. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4857-e4865.	1.8	10
97	Genetic Variation and Hot Flashes: A Systematic Review. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4907-e4957.	1.8	4
98	Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA). Menopause, 2020, 27, 1350-1356.	0.8	39
100	Association of hot flushes with ghrelin and adipokines in early versus late postmenopausal women. Menopause, 2020, 27, 512-518.	0.8	6
101	Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial. Menopause, 2020, 27, 498-505.	0.8	41
102	More promising news (mostly) on manipulating neurokinin B activity as a nonhormonal treatment of hot flashes. Menopause, 2020, 27, 375-376.	0.8	4
103	Lights on MsFLASH: a review of contributions. Menopause, 2020, 27, 473-484.	0.8	16
104	Temperature regulation in women: Effects of the menstrual cycle. Temperature, 2020, 7, 226-262.	1.6	75
105	Hypothalamic Astrocyte Development and Physiology for Neuroprogesterone Induction of the Luteinizing Hormone Surge. Frontiers in Endocrinology, 2020, 11, 420.	1.5	17
106	A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. Menopause, 2020, 27, 382-392.	0.8	57
107	Neurokinin 3 receptor antagonists â€“ prime time?. Climacteric, 2021, 24, 25-31.	1.1	11
108	The Menopause Transition: Signs, Symptoms, and Management Options. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1-15.	1.8	146
109	Managing menopausal vasomotor symptoms in older women. Maturitas, 2021, 143, 36-40.	1.0	14
110	Menopause Management. , 2021, , 1-14.		0

#	Article	IF	Citations
111	The human hypothalamic kisspeptin system: Functional neuroanatomy and clinical perspectives. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 180, 275-296.	1.0	8
112	The median preoptic nucleus: A major regulator of fluid, temperature, sleep, and cardiovascular homeostasis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 179, 435-454.	1.0	3
113	Neurokinin B. , 2021, , 123-124.		0
114	Regulation of Body Temperature. , 2021, , 6517-6520.		1
115	The neuroendocrinology of the preoptic area in menopause: Symptoms and therapeutic strategies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 179, 455-460.	1.0	4
116	Menopausal Vasomotor Symptoms and Risk of Incident Cardiovascular Disease Events in SWAN. Journal of the American Heart Association, 2021, 10, e017416.	1.6	56
117	Virtual Screening of Cablin Patchouli Herb as a Treatment for Heat Stress: A Study Based on Network Pharmacology, Molecular Docking, and Experimental Verification. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-14.	0.5	2
118	Estrogen Regulation of the Molecular Phenotype and Active Translatome of AVPV Kisspeptin Neurons. Endocrinology, 2021, 162, .	1.4	31
119	Long-term oral administration of a novel estrogen receptor beta agonist enhances memory and alleviates drug-induced vasodilation in young ovariectomized mice. Hormones and Behavior, 2021, 130, 104948.	1.0	12
120	QPLOT Neuronsâ€"Converging on a Thermoregulatory Preoptic Neuronal Population. Frontiers in Neuroscience, 2021, 15, 665762.	1.4	12
121	The risk of menopausal symptoms in premenopausal breast cancer patients and current pharmacological prevention strategies. Expert Opinion on Drug Safety, 2021, 20, 1163-1175.	1.0	3
123	Pharmacotherapeutic options for the treatment of menopausal symptoms. Expert Opinion on Pharmacotherapy, 2021, 22, 1773-1791.	0.9	2
124	The Effects of Estrogens on Neural Circuits That Control Temperature. Endocrinology, 2021, 162, .	1.4	21
126	Fezolinetant in the treatment of vasomotor symptoms associated with menopause. Expert Opinion on Investigational Drugs, 2021, 30, 681-694.	1.9	28
127	Gene expression analyses on multi-target mode of action of black cohosh in menopausal complaints â€“ a pilot study in rodents. Archives of Gynecology and Obstetrics, 2021, , 1.	0.8	4
128	Hypothalamic neurokinin signalling and its application in reproductive medicine. , 2022, 230, 107960.		10
129	Arcuate and Preoptic Kisspeptin Neurons Exhibit Differential Projections to Hypothalamic Nuclei and Exert Opposite Postsynaptic Effects on Hypothalamic Paraventricular and Dorsomedial Nuclei in the Female Mouse. ENeuro, 2021, 8, ENEURO.0093-21.2021.	0.9	16
130	Inhibiting Kiss1 Neurons With Kappa Opioid Receptor Agonists to Treat Polycystic Ovary Syndrome and Vasomotor Symptoms. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e328-e347.	1.8	13

#	Article	IF	Citations
131	Effects of neurokinin 3 receptor antagonist fezolinetant on hot flash-like symptoms in ovariectomized rats. European Journal of Pharmacology, 2021, 905, 174207.	1.7	5
132	Metabolic actions of kisspeptin signaling: Effects on body weight, energy expenditure, and feeding. , 2022, 231, 107974.		14
133	Neurokinin 3 Receptor Antagonists Compared With Serotonin Norepinephrine Reuptake Inhibitors for Non-Hormonal Treatment of Menopausal Hot Flushes: A Systematic Qualitative Review. Advances in Therapy, 2021, 38, 5025-5045.	1.3	17
134	Hormone Therapy in Menopause. Advances in Experimental Medicine and Biology, 2020, 1242, 89-120.	0.8	52
135	Purified and specific cytoplasmic pollen extract: a non-hormonal alternative for the treatment of menopausal symptoms. Gynecological Endocrinology, 2020, 36, 190-196.	0.7	11
136	Heterothermy is associated with reduced fitness in wild rabbits. Biology Letters, 2017, 13, 20170521.	1.0	19
137	Transcriptome Analysis of the Trachinotus ovatus: Identification of Reproduction, Growth and Immune-Related Genes and Microsatellite Markers. PLoS ONE, 2014, 9, e109419.	1.1	42
138	Detection of Successful and Unsuccessful Pregnancies in Mice within Hours of Pairing through Frequency Analysis of High Temporal Resolution Core Body Temperature Data. PLoS ONE, 2016, 11, e0160127.	1.1	40
139	Effect of acupuncture on hot flush and menopause symptoms in breast cancer- A systematic review and meta-analysis. PLoS ONE, 2017, 12, e0180918.	1.1	98
140	Circulating interleukin-8 and tumor necrosis factor-Î± are associated with hot flashes in healthy postmenopausal women. PLoS ONE, 2017, 12, e0184011.	1.1	32
141	MANAGEMENT OF ENDOCRINE DISEASE: Flushing: current concepts. European Journal of Endocrinology, 2017, 177, R219-R229.	1.9	13
142	Treating hot flushes with a neurokinin 3 receptor antagonist. Oncotarget, 2017, 8, 106153-106154.	0.8	6
143	Menopause and Brain Health: Hormonal Changes Are Only Part of the Story. Frontiers in Neurology, 2020, 11, 562275.	1.1	28
144	Rola sygnalizacji kisspeptyny w osi podwzgÃ³rzeâ€“przysadkaâ€“nadnercza â€” aktualna perspektywa. Endokrynologia Polska, 2015, 66, 534-547.	0.3	28
145	Features of the ovulatory function restoration in women. Reproductive Endocrinology, 2021, , 96-100.	0.0	0
146	The menopausal transition in Mongolia. Menopause, 2022, 29, 96-100.	0.8	0
147	Neurokinin B-expressing neurons of the central extended amygdala mediate inhibitory synaptic input onto melanin-concentrating hormone neuron subpopulations. Journal of Neuroscience, 2021, 41, JN-RM-2600-20.	1.7	3
148	Nonhormonal Pharmacotherapies for Menopause Management. , 2017, , 45-65.		0

#	Article	IF	Citations
149	Pathophysiology of hot flashes with focus on neurohormonal regulation (a review). Russian Journal of Human Reproduction, 2017, 23, 115.	0.1	4
150	Membrane-Initiated Effects of Estradiol in the Central Nervous System. , 2017, , 1-22.		0
151	Clinical Symptoms and Quality of Life: Hot Flashes and Mood. , 2017, , 69-78.		2
153	Traitements non hormonaux des bouffÃ©es vasomotrices. , 2019, , 311-316.		0
154	Regulation of Body Temperature. , 2020, , 1-5.		0
155	Hypertensive disorders of pregnancy and menopausal symptoms: a cross-sectional study from the data registry on experiences of aging, menopause, and sexuality. Menopause, 2021, 28, 25-31.	0.8	6
156	Etiological and pathogenetic factors of ovarian dysfunction in women of reproductive age. Russian Journal of Human Reproduction, 2020, 26, 34.	0.1	3
158	Establishment of a non-human primate model for menopausal hot flushes. , 2020, 9, .		0
159	Menopause review: Emerging treatments for menopausal symptoms. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2022, 81, 134-144.	1.4	11
160	Contemporary Non-hormonal Therapies for the Management of Vasomotor Symptoms Associated with Menopause: A Literature Review. European Endocrinology, 2021, 17, 133.	0.8	9
161	The Role of Acupuncture in Hormonal Shock-Induced Cognitive-Related Symptoms in Perimenopausal Depression: A Randomized Clinical Controlled Trial. Frontiers in Psychiatry, 2021, 12, 772523.	1.3	2
162	A Clinical Review on Paroxetine and Emerging Therapies for the Treatment of Vasomotor Symptoms. International Journal of Women's Health, 2022, Volume 14, 353-361.	1.1	5
163	Menopause transition: Physiology and symptoms. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2022, 81, 3-7.	1.4	43
164	Kappa-Opioid Receptor Blockade Ameliorates Obesity Caused by Estrogen Withdrawal via Promotion of Energy Expenditure through mTOR Pathway. International Journal of Molecular Sciences, 2022, 23, 3118.	1.8	7
165	Estradiol and Estrogen-like Alternative Therapies in Use: The Importance of the Selective and Non-Classical Actions. Biomedicines, 2022, 10, 861.	1.4	18
166	Treat more than heatâ€"New therapeutic implications of Cimicifuga racemosa through AMPK-dependent metabolic effects. Phytomedicine, 2022, 100, 154060.	2.3	4
167	The roles of kisspeptin and neurokinin B in GnRH pulse generation in humans, and their potential clinical application. Journal of Neuroendocrinology, 2022, 34, e13081.	1.2	9
168	Hypothalamic Kisspeptin Neurons and the Control of Homeostasis. Endocrinology, 2022, 163, .	1.4	12

#	Article	IF	Citations
169	Shared genetic influences on depression and menopause symptoms. Psychological Medicine, 2023, 53, 2241-2251.	2.7	7
170	Dissecting the Molecular Mechanisms Surrounding Post-COVID-19 Syndrome and Neurological Features. International Journal of Molecular Sciences, 2022, 23, 4275.	1.8	20
171	Birth, love, and fear: Physiological networks from pregnancy to parenthood. Comprehensive Psychoneuroendocrinology, 2022, 11, 100138.	0.7	6
172	Treating menopause â€" MHT and beyond. Nature Reviews Endocrinology, 2022, 18, 490-502.	4.3	37
174	Resistance training reduced luteinising hormone levels in postmenopausal women in a substudy of a randomised controlled clinical trial: A clue to how resistance training reduced vasomotor symptoms. PLoS ONE, 2022, 17, e0267613.	1.1	3
175	Kisspeptin neuron electrophysiology: Intrinsic properties, hormonal modulation, and regulation of homeostatic circuits. Frontiers in Neuroendocrinology, 2022, 66, 101006.	2.5	6
177	Transcriptome profiling of kisspeptin neurons from the mouse arcuate nucleus reveals new mechanisms in estrogenic control of fertility. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	11
178	Kisspeptin Modulation of Reproductive Function. Endocrines, 2022, 3, 367-374.	0.4	4
179	The interplay between diabetes mellitus and menopause: clinical implications. Nature Reviews Endocrinology, 2022, 18, 608-622.	4.3	25
180	Hormonal Agents for the Treatment of Depression Associated with the Menopause. Drugs and Aging, 2022, 39, 607-618.	1.3	15
182	Impact of lifetime lactation on the risk and duration of frequent vasomotor symptoms: A longitudinal doseâ€"response analysis. BJOG: an International Journal of Obstetrics and Gynaecology, 0, , .	1.1	0
183	Menopausal vasomotor symptoms and adiponectin among midlife women. Menopause, 2022, 29, 1145-1149.	0.8	2
184	Stress, kisspeptin, and functional hypothalamic amenorrhea. Current Opinion in Pharmacology, 2022, 67, 102288.	1.7	11
185	Prior aerobic physical training modulates neuropeptide expression and central thermoregulation after ovariectomy in the rat. Molecular and Cellular Endocrinology, 2022, 558, 111756.	1.6	0
186	Deletion of Growth Hormone Secretagogue Receptor in Kisspeptin Neurons in Female Mice Blocks Diet-Induced Obesity. Biomolecules, 2022, 12, 1370.	1.8	4
187	Essential Role of Histidine for Rapid Copper(II)-Mediated Disassembly of Neurokinin B Amyloid. Biomolecules, 2022, 12, 1585.	1.8	2
188	Estrogen as a key regulator of energy homeostasis and metabolic health. Biomedicine and Pharmacotherapy, 2022, 156, 113808.	2.5	21
189	Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet, The, 2022, 400, 1704-1711.	6.3	6

#	Article	IF	Citations
190	Targeting KNDy neurons to control GnRH pulses. Current Opinion in Pharmacology, 2022, 67, 102316.	1.7	3
191	Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1). Menopause, 2023, 30, 239-246.	0.8	12
192	Physical activity and exercise for hot flashes: trigger or treatment?. Menopause, 2023, 30, 218-224.	0.8	7
193	Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT. Journal of Clinical Endocrinology and Metabolism, 2023, 108, 1981-1997.	1.8	42
194	Continuing progress on vasomotor symptoms. Menopause, 2023, 30, 235-236.	0.8	0
195	Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms. Lancet, The, 2023, 401, 1055-1058.	6.3	0
196	Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet, The, 2023, 401, 1091-1102.	6.3	49
197	Optimizing sleep across the menopausal transition. Climacteric, 0, , 1-8.	1.1	0
198	New advances in menopause symptom management. Best Practice and Research in Clinical Endocrinology and Metabolism, 2024, 38, 101774.	2.2	3
199	Vasomotor symptoms and their links to cardiovascular disease risk. Current Opinion in Endocrine and Metabolic Research, 2023, 30, 100448.	0.6	1
210	Are novel treatments for brain disorders hiding in plain sight?. Neuropsychopharmacology, 0, , .	2.8	0